Entod Pharmaceuticals gets DCGI approval for eye drops to treat presbyopia

Q: How long will it take to read this news story?

The story "Entod Pharmaceuticals gets DCGI approval for eye drops to treat presbyopia" has 568 words across 21 sentences, which will take approximately 3 - 5 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Entod Pharmaceuticals gets DCGI approval for eye drops to treat presbyopia" was covered 7 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 348 news stories per day. It's most recent story was published 3 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #22348897</li><li>URL: https://beamstart.com/news/entod-pharmaceuticals-gets-dcgi-approval-172537324</li></ul>

Business Standard Logo Business Standard 7h ago

Entod Pharmaceuticals gets DCGI approval for eye drops to treat presbyopia - Business Standard

Quick Summary:

Entod Pharmaceuticals on Tuesday said it has received approval from the Drug Controller General of India (DCGI) to market eye drops for the treatment of presbyopia.

The Mumbai-based drugmaker has received a final approval for PresVu eye drops and plans to introduce it in the domestic market in the first week of October.

PresVu is the first eye drop in India specifically developed to reduce dependency on reading glasses for individuals affected by presbyopia, a common age-related vision condition that typically impacts those over 40.